History
In the mid-1970s, Harvey J. Alter, Chief of the Infectious Disease Section in the Department of Transfusion Medicine at the National Institutes of Health, and his research team demonstrated how most post-transfusion hepatitis cases were not due to hepatitis A or B viruses. Despite this discovery, international research efforts to identify the virus, initially called non-A, non-B hepatitis (NANBH), failed for the next decade. In 1987, Michael Houghton, Qui-Lim Choo, and George Kuo at Chiron Corporation, collaborating with Dr. D.W. Bradley at the Centers for Disease Control and Prevention, used a novel molecular cloning approach to identify the unknown organism and develop a diagnostic test.
In 1988, the virus was confirmed by Alter by verifying its presence in a
panel of NANBH specimens. In April 1989, the discovery of HCV was
published in two articles in the journal Science.The discovery led to significant improvements in diagnosis and improved antiviral treatment. In 2000, Drs. Alter and Houghton were honored with the Lasker Award for Clinical Medical Research
for "pioneering work leading to the discovery of the virus that causes
hepatitis C and the development of screening methods that reduced the
risk of blood transfusion-associated hepatitis in the U.S. from 30% in
1970 to virtually zero in 2000."
Chiron filed for several patents on the virus and its diagnosis.A competing patent application by the CDC was dropped in 1990 after
Chiron paid $1.9 million to the CDC and $337,500 to Bradley. In 1994,
Bradley sued Chiron, seeking to invalidate the patent, have himself
included as a coinventor, and receive damages and royalty income. He
dropped the suit in 1998 after losing before an appeals court.
No comments:
Post a Comment